GlassScriptPhysician profile
Donna K Maneice
NPI 1932288339
$20,682.51
in general payments reported to CMS, 2019-2025
34 companies · $3,797 in 2025
The $3,797 reported for 2025 was more than what 82% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,006 · 2020: $1,934 · 2021: $2,814 · 2022: $2,872 · 2023: $3,347 · 2024: $2,912 · 2025: $3,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,843 · Education: $213.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,843.42 |
| Education | $212.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,758.79 | 2019-2025 | |
| Amgen INC. | $3,319.41 | 2019-2025 | Krystexxa, Enbrel, Evenity |
| Mallinckrodt Hospital Products INC. | $2,122.51 | 2020-2025 | Acthar |
| Ucb, INC. | $1,563.13 | 2019-2025 | Cimzia, Bimzelx |
| Novartis Pharmaceuticals Corporation | $1,180.56 | 2019-2025 | |
| Janssen Biotech, INC. | $1,141.72 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Pfizer INC. | $1,031.33 | 2019-2025 | |
| Glaxosmithkline, LLC. | $992.99 | 2019-2025 | Benlysta |
| E.R. Squibb & Sons, L.L.C. | $781.37 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $673.06 | 2019-2023 | Krystexxa |
| Lilly USA, LLC | $649.92 | 2019-2025 | Taltz, Zepbound, Olumiant |
| Astrazeneca Pharmaceuticals LP | $561.27 | 2021-2025 | Saphnelo |
| Ani Pharmaceuticals, INC. | $439.95 | 2022-2025 | Purified Cortrophin Gel |
| Radius Health, INC. | $406.28 | 2019-2025 | Tymlos |
| Genentech USA, INC. | $378.91 | 2019-2025 | Actemra, Gazyva |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aurinia Pharma U.S., INC. | $355.25 | 2021-2025 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $288.71 | 2019-2025 | Ofev |
| Mallinckrodt Enterprises LLC | $211.19 | 2019 | |
| Genzyme Corporation | $191.41 | 2023-2025 | |
| Celgene Corporation | $142.48 | 2019 | |
| Organon LLC | $96.39 | 2023-2025 | Hadlima, Renflexis, Nexplanon |
| Alexion Pharmaceuticals, INC. | $64.25 | 2022-2024 | Strensiq |
| Medexus Pharma, INC. | $58.86 | 2019-2020 | |
| Sandoz INC. | $50.92 | 2023 | Hyrimoz |
| Daiichi Sankyo INC. | $36.25 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $34.17 | 2019 | |
| Bioventus LLC | $25.56 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $24.36 | 2020 | |
| Eusa Pharma (US) LLC | $22.37 | 2019 | |
| Pacira Therapeutics, INC. | $21.10 | 2019 | |
| Kyowa Kirin, INC. | $18.94 | 2025 | |
| United Therapeutics Corporation | $14.52 | 2022 | |
| Boston Scientific Corporation | $13.19 | 2023 | Infinion 16 |
| Takeda Pharmaceuticals U.S.A., INC. | $11.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Maneice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.